Moderna (MRNA) Share-based Compensation (2018 - 2026)

Moderna (MRNA) has 9 years of Share-based Compensation data on file, last reported at $2.0 million in Q1 2026.

• On a quarterly basis, Share-based Compensation fell 98.26% year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $370.0 million, a 31.99% decrease from a year earlier, with the FY2025 full-year figure at $483.0 million, up 12.59% from the prior year.
• Share-based Compensation for Q1 2026 stood at $2.0 million, down from $113.0 million in the prior quarter.
• Over the last five years, Share-based Compensation for MRNA reached as high as $429.0 million in Q4 2024 and fell as low as $2.0 million in Q1 2026.
• Historically, Share-based Compensation has averaged $103.2 million across 5 years, with a median of $76.0 million in 2023.
• Across the five-year window, Share-based Compensation surged 443.04% in 2024 and tumbled 98.26% in 2026, its largest moves.
• Year by year, Share-based Compensation stood at $62.0 million in 2022, then increased by 27.42% to $79.0 million in 2023, then jumped by 443.04% to $429.0 million in 2024, then slumped by 73.66% to $113.0 million in 2025, then slumped by 98.23% to $2.0 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $2.0 million in Q1 2026, $113.0 million in Q4 2025, and $125.0 million in Q3 2025.